Point

Impact of prostate-specific antigen velocity on management decisions and recommendations

Research output: Contribution to journalArticle

Abstract

Prostate-specific antigen (PSA) velocity predicts the presence of prostate cancer on biopsy and a greater risk of prostate cancer death after radical treatment. A new variation on PSA velocity called the risk count was recently shown to provide incremental reclassification for intermediate to high-grade disease on biopsy beyond PSA and age. These markers therefore have the potential to reduce overdiagnosis and overtreatment of indolent prostate cancer, and several professional guidelines support the use of PSA kinetics along with other predictors as part of the diagnostic algorithm. Among men already diagnosed with prostate cancer, PSA kinetics may also be helpful in predicting prognosis after definitive therapy.

Original languageEnglish (US)
Pages (from-to)281-285
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue number3
StatePublished - Mar 1 2013

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Biopsy
Guidelines
Therapeutics
Medical Overuse

ASJC Scopus subject areas

  • Oncology

Cite this

@article{212feb36e5f040a58b8b37431eea3137,
title = "Point: Impact of prostate-specific antigen velocity on management decisions and recommendations",
abstract = "Prostate-specific antigen (PSA) velocity predicts the presence of prostate cancer on biopsy and a greater risk of prostate cancer death after radical treatment. A new variation on PSA velocity called the risk count was recently shown to provide incremental reclassification for intermediate to high-grade disease on biopsy beyond PSA and age. These markers therefore have the potential to reduce overdiagnosis and overtreatment of indolent prostate cancer, and several professional guidelines support the use of PSA kinetics along with other predictors as part of the diagnostic algorithm. Among men already diagnosed with prostate cancer, PSA kinetics may also be helpful in predicting prognosis after definitive therapy.",
author = "Stacy Loeb and Carter, {H Ballentine}",
year = "2013",
month = "3",
day = "1",
language = "English (US)",
volume = "11",
pages = "281--285",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "3",

}

TY - JOUR

T1 - Point

T2 - Impact of prostate-specific antigen velocity on management decisions and recommendations

AU - Loeb, Stacy

AU - Carter, H Ballentine

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Prostate-specific antigen (PSA) velocity predicts the presence of prostate cancer on biopsy and a greater risk of prostate cancer death after radical treatment. A new variation on PSA velocity called the risk count was recently shown to provide incremental reclassification for intermediate to high-grade disease on biopsy beyond PSA and age. These markers therefore have the potential to reduce overdiagnosis and overtreatment of indolent prostate cancer, and several professional guidelines support the use of PSA kinetics along with other predictors as part of the diagnostic algorithm. Among men already diagnosed with prostate cancer, PSA kinetics may also be helpful in predicting prognosis after definitive therapy.

AB - Prostate-specific antigen (PSA) velocity predicts the presence of prostate cancer on biopsy and a greater risk of prostate cancer death after radical treatment. A new variation on PSA velocity called the risk count was recently shown to provide incremental reclassification for intermediate to high-grade disease on biopsy beyond PSA and age. These markers therefore have the potential to reduce overdiagnosis and overtreatment of indolent prostate cancer, and several professional guidelines support the use of PSA kinetics along with other predictors as part of the diagnostic algorithm. Among men already diagnosed with prostate cancer, PSA kinetics may also be helpful in predicting prognosis after definitive therapy.

UR - http://www.scopus.com/inward/record.url?scp=84875889881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875889881&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 281

EP - 285

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 3

ER -